Cargando…
Glargine-300: An updated literature review on randomized controlled trials and real-world studies
Despite the availability of a variety of insulins, rates of insulinisation and the acceptance of insulin therapy is suboptimal in real-world clinical settings. Patient and physician concerns with hypoglycaemia and weight gain are the two key issues that serve to impede appropriate insulinisation in...
Autores principales: | Ghosh, Sujoy, Ghosh, Romik |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7156297/ https://www.ncbi.nlm.nih.gov/pubmed/32313609 http://dx.doi.org/10.4239/wjd.v11.i4.100 |
Ejemplares similares
-
Real-World Effectiveness of Insulin Glargine 300 Initiation in Switzerland
por: Thomann, Robert, et al.
Publicado: (2020) -
Insulin glargine 300 units/mL for the treatment of individuals with type 2 diabetes in the real world: A review of the DELIVER programme
por: Blonde, Lawrence, et al.
Publicado: (2021) -
How many people with type 2 diabetes fulfil the eligibility criteria for randomized, controlled trials of insulin glargine 300 U/mL in a real‐world setting?
por: Mauricio, Dídac, et al.
Publicado: (2020) -
Improved Glycemic Control with Insulin Glargine 300 U/mL (Toujeo(®)) in Patients with Type 2 Diabetes: Real-World Effectiveness in Switzerland
por: Wiesli, Peter, et al.
Publicado: (2018) -
rDNA insulin glargine U300 – a critical appraisal
por: Wang, Fei, et al.
Publicado: (2016)